Trosolwyg
I am a Clinical Senior Lecturer in Colorectal Surgery and a member of the Cardiff China Medical Research Collaborative (CCMRC). My clinical practice is performed mainly at University Hospital of Wales, with day surgery and clinic commitments at Llandough and Velindre hospitals respectively. I run a large, tertiary colorectal practice with special interests in colorectal and anal cancer, genetic disorders which predispose to colorectal cancer, redo and damage limitation surgery, the “catastrophe abdomen” and intestinal failure and complex proctology including fistulae.
I collaborate with other members of CCMRC in studying the mechanisms by which tumours can metastasize (spread) throughout the body. I jointly supervise PhD and MD students, and coordinate clinical placements for visiting overseas post graduate students and doctors.
As part of the delivery of C21 undergraduate education I coordinate and provide placements for both Cardiff MB BCh and elective students from many parts of the world.
Cyhoeddiad
2025
- McKenna, M. et al. 2025. Human equilibrative nucleoside transporter 1 and concentrative nucleoside transporter 1 in colorectal cancer: What do we know? A systematic review. Histology and Histopathology 40 (10.14670/HH-18-881)
2024
- Gould, H. L. et al. 2024. Earlier diagnosis of small intestine neuroendocrine tumours (SI-NETs) through transformation of the South Wales NET service. Journal of Neuroendocrinology (10.1111/jne.13486)
- Ifeanyichi, M. et al. 2024. Cost-effectiveness of surgical interventions in low-income and middle-income countries: a systematic review and critical analysis of recent evidence. BMJ Global Health 9(10), article number: bmjgh-2024-016439. (10.1136/bmjgh-2024-016439)
2023
- Kebede, M. A. et al. 2023. Identifying critical gaps in research to advance global surgery by 2030: a systematic mapping review. BMC Health Services Research 23, article number: 946. (10.1186/s12913-023-09973-9)
- Clark, S. et al. 2023. Hereditary gastrointestinal polyposis syndromes Rare Disease Collaborative Network consensus statement agreed at the RDCN meeting Birmingham 17th February 2022. BJC Reports 1(1), article number: 10. (10.1038/s44276-023-00011-z)
- Fang, Z., Zeng, J. J., Yang, Y., Ruge, F., Lane, J., Hargest, R. and Jiang, W. 2023. Expression of ALCAM in clinical colon cancer and relationship with patients' treatment responses. In Vivo 37(3), pp. 1117-1128. (10.21873/invivo.13187)
- Hargest, R. 2023. Surgery is the standard of care for early rectal cancer. Clinical Oncology 35(2), pp. 75-79. (10.1016/j.clon.2022.11.016)
- Davis, F., Zabkiewicz, C. and Hargest, R. 2023. GREM1 in HER2+ breast cancer: worse prognosis, larger tumours and more bone metastasis. European Journal of Surgical Oncology 49(1), article number: E2. (10.1016/j.ejso.2022.11.018)
2022
- Zeng, J., Sanders, A. J., Lin, Y., Hargest, R., Ruge, F. and Jiang, W. G. 2022. EPLIN, a putative tumour suppressor in colorectal cancer, implications in drug resistance. International Journal of Molecular Sciences 23(23), article number: 15232. (10.3390/ijms232315232)
- Sui, L. et al. 2022. Death associated protein-3 (DAP3) and DAP3 binding cell death enhancer-1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance. International Journal of Oncology 62(1), article number: 7. (10.3892/ijo.2022.5455)
- Sui, L., Zeng, J., Ye, L., Martin, T., Jiang, W. and Hargest, R. 2022. P-282 Impact of death-associated protein-3 (DAP3) and DAP3 binding cell death enhancer 1 (DELE1) on drug sensitivity in colorectal cancer cells. Annals of Oncology 33, pp. S347. (10.1016/j.annonc.2022.04.371)
- Soliman, F., Ye, L., Jiang, W. and Hargest, R. 2022. Targeting hyaluronic acid and peritoneal dissemination in colorectal cancer. Clinical Colorectal Cancer 21(2), pp. e126-e134. (10.1016/j.clcc.2021.11.008)
2021
- Martin, T. A., Li, A. X., Sanders, A. J., Ye, L., Frewer, K., Hargest, R. and Jiang, W. G. 2021. NUPR1 and its potential role in cancer and pathological conditions (Review). International Journal of Oncology 58(5), article number: 21. (10.3892/ijo.2021.5201)
- Sui, L., Ye, L., Sanders, A. J., Yang, Y., Hao, C., Hargest, R. and Jiang, W. G. 2021. Expression of death associated proteins DAP1 and DAP3 in human pancreatic cancer. Anticancer Research 41(5), pp. 2357-2362. (10.21873/anticanres.15010)
- Liu, C., Jiang, W., Zhang, L., Hargest, R. and Martin, T. A. 2021. SIPA1 Is a modulator of HGF/MET induced tumour metastasis via the regulation of tight junction-based cell to cell barrier function. Cancers 13(7), article number: 1747. (10.3390/cancers13071747)
- Hargest, R. 2021. Five thousand years of minimal access surgery: 1850 to 1990: Technological developments. Journal of the Royal Society of Medicine 114(1), pp. 19-29. (10.1177/0141076820967918)
2020
- Gong, W., Martin, T. A., Sanders, A. J., Hargest, R., Jiang, A., Sun, P. and Jiang, W. G. 2020. Influence of anaesthetics on the production of cancer cell motogens, stromal cell-derived factor-1 and hepatocyte growth factor by fibroblasts. Oncology Letters 21(2), article number: 140. (10.3892/ol.2020.12401)
- Liu, C., Jiang, W., Hargest, R. and Martin, T. 2020. The role of SIPA1 in the development of cancer and metastases (Review). Molecular and Clinical Oncology 13(4), article number: 32. (10.3892/mco.2020.2102)
- Badder, L. M. et al. 2020. 3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitors. PLoS ONE 15(8), article number: e0235319. (10.1371/journal.pone.0235319)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
2019
- Besneux, M. et al. 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68, pp. 247-256. (10.1007/s00262-018-2266-1)
2018
- Soliman, F. and Hargest, R. 2018. Intestinal failure in gastrointestinal fistula patients. Surgery (Oxford) 36(5), pp. 245-251. (10.1016/j.mpsur.2018.03.001)
- Sahnan, K. et al. 2018. Developing a core outcome set for fistulising perianal Crohn's disease. Gut (10.1136/gutjnl-2017-315503)
- Hargest, R. 2018. Randomized controlled trial of standard closure of a stoma site vs biological mesh reinforcement: study protocol of the ROCSS trial. Colorectal Disease 20(2), pp. O46-O54. (10.1111/codi.13997)
2017
- Osman, B., Roushias, S., Hargest, R. and Narahari, K. 2017. Migration of ventriculoperitoneal shunt to urethral and rectal orifices. BMJ Case Reports 2017, article number: 220187. (10.1136/bcr-2017-220187)
- Zabkiewicz, C., Resaul, J., Hargest, R., Jiang, W. G. and Ye, L. 2017. Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. Endocrine-Related Cancer 24(10), pp. R349-R366. (10.1530/ERC-17-0139)
- Zabkiewicz, C., Resaul, J., Hargest, R., Jiang, W. G. and Ye, L. 2017. Increased expression of follistatin in breast cancer reduces invasiveness and clinically correlates with better survival. Cancer Genomics and Proteomics 14(4), pp. 241-251. (10.21873/cgp.20035)
- Lee, M., Heywood, N., Sagar, P. M., Brown, S. R., Fearnhead, N. and Hargest, R. 2017. Association of Coloproctology of Great Britain and Ireland consensus exercise on surgical management of fistulating perianal Crohn's disease. Colorectal Disease 19(5), pp. 418-429. (10.1111/codi.13672)
- Gu, Y. et al. 2017. NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. Oncotarget 8(5), pp. 7753-7765. (10.18632/oncotarget.13949)
2016
- Hargest, R. 2016. Feasibility study from a randomized controlled trial of standard closure of a stoma sitevsbiological mesh reinforcement. Colorectal Disease 18(9), pp. 889-896. (10.1111/codi.13310)
- Cornish, J. et al. 2016. Hughes Abdominal Repair Trial (HART) - Abdominal wall closure techniques to reduce the incidence of incisional hernias: study protocol for a randomised controlled trial. Trials 17(1), pp. 454. (10.1186/s13063-016-1573-0)
- Teagle, A. R., Birchall, J. C. and Hargest, R. 2016. Gene therapy for pyoderma gangrenosum: optimal transfection conditions and effect of drugs on gene delivery in the HaCaT cell line using cationic liposomes. Skin Pharmacology and Physiology 29, pp. 119-129. (10.1159/000444859)
- Satherley, L., Sun, P. H., Ke, J., Mason, M. D., Hargest, R., Jiang, W. G. and Ye, L. 2016. Prostate Apoptosis Response-4 (PAR4) suppresses growth and invasion of breast cancer cells and is positively associated with patient survival. Anticancer Research 36(3), pp. 1227-1236.
- Greensmith, M., Cho, J. and Hargest, R. 2016. Changes in surgical training opportunities in Britain and South Africa. International Journal of Surgery 25, pp. 76-81. (10.1016/j.ijsu.2015.11.052)
2015
- Collins, R. J., Jiang, W. G., Hargest, R., Mason, M. D. and Sanders, A. J. 2015. EPLIN: a fundamental actin regulator in cancer metastasis?. Cancer and Metastasis Reviews 34(4), pp. 753-764. (10.1007/s10555-015-9595-8)
- Soliman, F., Sturgeon, G. and Hargest, R. 2015. Revisiting an ancient treatment for transphincteric fistula-in-ano 'There is nothing new under the sun' Ecclesiastes 1v9. Journal of the Royal Society of Medicine 108(12), pp. 482-489. (10.1177/0141076815588322)
- Li, J., Ye, L., Sun, P., Satherley, L., Hargest, R., Zhang, Z. and Jiang, W. G. 2015. MTA1 is up-regulated in colorectal cancer and is inversely correlated with lymphatic metastasis. Cancer Genomics and Proteomics 12(6), pp. 339-346.
- Satherley, L., Ye, L., Hargest, R. and Jiang, W. G. 2015. Downstream of tyrosine kinase 7 (DOK7) variant expression and function in human colorectal cancer [Abstract]. European Journal of Cancer 51(S3), pp. S27. (10.1016/S0959-8049(15)30004-6)
- Ji, J., Jia, S., Jia, Y., Ji, K., Hargest, R. and Jiang, W. G. 2015. WISP-2 in human gastric cancer and its potential metastatic suppressor role in gastric cancer cells mediated by JNK and PLC-γ pathways. British Journal of Cancer 113(6), pp. 921-933. (10.1038/bjc.2015.285)
- Ji, K., Cui, Y., Hargest, R. and Jiang, W. G. 2015. VILIP-1 plays a suppressive role in the motility of colorectal cancer cells and the inhibition involves the regulation of mmps via jnk signalling pathway. Anticancer Research 35(7), pp. 4332-4333.
- Satherley, L., Jiang, W. G., Hargest, R., Torkington, J. and Davies, M. 2015. Expression of lymphangiogenic factors Vegf-C and Vegf-D and impact of Vegf-D knockout on tubule formation in human colorectal cancer [Abstract]. British Journal of Surgery 102(s1), pp. 8-8., article number: 700. (10.1002/bjs.9735)
2014
- Teagle, A. and Hargest, R. 2014. Management of pyoderma gangrenosum. Journal of the Royal Society of Medicine 107(6), pp. 228-236. (10.1177/0141076814534407)
- Satherley, L., Ye, L., Hargest, R. and Jiang, W. G. 2014. DOK7 expression in colorectal cancer cells and association with clinical and prognostic outcome [Abstract]. British Journal of Surgery 101(S4), pp. 12., article number: O34. (10.1002/bjs.9508)
- Jia, Y., Ye, L., Ji, K., Zhang, L., Hargest, R., Ji, J. and Jiang, W. G. 2014. Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. British Journal of Cancer 110(2), pp. 421-429. (10.1038/bjc.2013.712)
- Power, K., Davies, M. M., Hargest, R., Phillips, S., Torkington, J. and Morris, C. 2014. A case-control study of risk factors for wound infection in a colorectal unit. Annals of the Royal College of Surgeons of England 96(1), pp. 37-40. (10.1308/003588414X13824511650137)
- Jia, Y. et al. 2014. Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death. Oncology Reports 31(1), pp. 175-182. (10.3892/or.2013.2866)
- Ji, K., Ye, L., Ruge, F., Hargest, R., Mason, M. D. and Jiang, W. G. 2014. Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer. BMC Cancer 14, article number: 723. (10.1186/1471-2407-14-723)
2013
- Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
- Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
- Frewer, N. et al. 2013. Potential implication of IL-24 in lymphangiogenesis of human breast cancer. International Journal of Molecular Medicine 31(5), pp. 1097-1104. (10.3892/ijmm.2013.1319)
- Chong, R. et al. 2013. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. Journal of Controlled Release 166(3), pp. 211-219. (10.1016/j.jconrel.2012.12.030)
- Frewer, K., Sanders, A. J., Owen, S., Frewer, N., Hargest, R. and Jiang, W. G. 2013. A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics and Proteomics 10(4), pp. 187-196.
- Chong, R. H. et al. 2013. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. Journal of Controlled Release 166(3), pp. 211. (10.1016/j.jconrel.2012.12.030)
2012
- Blake, P., Delicata, R., Cross, N., Sturgeon, G. and Hargest, R. 2012. Large bowel obstruction due to colorectal carcinoma can be safely treated by colonic stent insertion - case series from a UK district general hospital. Colorectal Disease 14(12), pp. 1489-1492. (10.1111/j.1463-1318.2012.03035.x)
- Ji, K. et al. 2012. Expression of signal-induced proliferation-associated gene 1 (SIPA1), a rapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. Cancer Genomics and Proteomics 9(5), pp. 321-327.
2011
- Chong, R., Coulman, S., Saller, V., Pearton, M., Shah, A., Hargest, R. and Birchall, J. C. 2011. Nucleic acid delivery to skin for the potential treatment of dermatopathogenic conditions [Abstract]. Human Gene Therapy 22(10), pp. A82-A82.
- Teagle, A., Birchall, J. C. and Hargest, R. 2011. The effect of drugs commonly used for pyoderma gangrenosum on the efficiency of gene transfer to human keratinocytes. Human Gene Therapy 22(10), pp. A94-A94.
- Teagle, A., Birchall, J. C. and Hargest, R. 2011. The effect of drugs commonly used for pyoderma gangrenosum on the efficiency of gene transfer to human keratinocytes [Abstract]. British Journal of Surgery 98, pp. 40-40. (10.1002/bjs.7577/abstract)
2010
- Hardwicke, J., Wright, T. C., Hargest, R. and Dickson, W. 2010. The use of the Flexi-Seal®Faecal Management System in laparostomy wounds involving enterocutaneous fistula. Annals of the Royal College of Surgeons of England 92(4), pp. e12-e14. (10.1308/147870810X12659688851834)
- Zimbwa, T. A., Owen, R., Thomas, G., Hargest, R. and Williams, G. T. 2010. An unusual complication of colitis. Gut 59(3), pp. 364-364. (10.1136/gut.2009.179689)
2009
- Stephens, M. and Hargest, R. 2009. The post-CCT subconsultant grade: the case against / the case for. Bulletin of The Royal College of Surgeons of England 91(4), pp. 124-126. (10.1308/147363509X423788)
2008
- Ganapathi, S., Evans, G. and Hargest, R. 2008. Bilateral breast metastases of a renal carcinoma: a case report and review of the literature. BMJ Case Reports 2008(Nov 12), article number: bcr0620080239. (10.1136/bcr.06.2008.0239)
Erthyglau
- McKenna, M. et al. 2025. Human equilibrative nucleoside transporter 1 and concentrative nucleoside transporter 1 in colorectal cancer: What do we know? A systematic review. Histology and Histopathology 40 (10.14670/HH-18-881)
- Gould, H. L. et al. 2024. Earlier diagnosis of small intestine neuroendocrine tumours (SI-NETs) through transformation of the South Wales NET service. Journal of Neuroendocrinology (10.1111/jne.13486)
- Ifeanyichi, M. et al. 2024. Cost-effectiveness of surgical interventions in low-income and middle-income countries: a systematic review and critical analysis of recent evidence. BMJ Global Health 9(10), article number: bmjgh-2024-016439. (10.1136/bmjgh-2024-016439)
- Kebede, M. A. et al. 2023. Identifying critical gaps in research to advance global surgery by 2030: a systematic mapping review. BMC Health Services Research 23, article number: 946. (10.1186/s12913-023-09973-9)
- Clark, S. et al. 2023. Hereditary gastrointestinal polyposis syndromes Rare Disease Collaborative Network consensus statement agreed at the RDCN meeting Birmingham 17th February 2022. BJC Reports 1(1), article number: 10. (10.1038/s44276-023-00011-z)
- Fang, Z., Zeng, J. J., Yang, Y., Ruge, F., Lane, J., Hargest, R. and Jiang, W. 2023. Expression of ALCAM in clinical colon cancer and relationship with patients' treatment responses. In Vivo 37(3), pp. 1117-1128. (10.21873/invivo.13187)
- Hargest, R. 2023. Surgery is the standard of care for early rectal cancer. Clinical Oncology 35(2), pp. 75-79. (10.1016/j.clon.2022.11.016)
- Davis, F., Zabkiewicz, C. and Hargest, R. 2023. GREM1 in HER2+ breast cancer: worse prognosis, larger tumours and more bone metastasis. European Journal of Surgical Oncology 49(1), article number: E2. (10.1016/j.ejso.2022.11.018)
- Zeng, J., Sanders, A. J., Lin, Y., Hargest, R., Ruge, F. and Jiang, W. G. 2022. EPLIN, a putative tumour suppressor in colorectal cancer, implications in drug resistance. International Journal of Molecular Sciences 23(23), article number: 15232. (10.3390/ijms232315232)
- Sui, L. et al. 2022. Death associated protein-3 (DAP3) and DAP3 binding cell death enhancer-1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance. International Journal of Oncology 62(1), article number: 7. (10.3892/ijo.2022.5455)
- Sui, L., Zeng, J., Ye, L., Martin, T., Jiang, W. and Hargest, R. 2022. P-282 Impact of death-associated protein-3 (DAP3) and DAP3 binding cell death enhancer 1 (DELE1) on drug sensitivity in colorectal cancer cells. Annals of Oncology 33, pp. S347. (10.1016/j.annonc.2022.04.371)
- Soliman, F., Ye, L., Jiang, W. and Hargest, R. 2022. Targeting hyaluronic acid and peritoneal dissemination in colorectal cancer. Clinical Colorectal Cancer 21(2), pp. e126-e134. (10.1016/j.clcc.2021.11.008)
- Martin, T. A., Li, A. X., Sanders, A. J., Ye, L., Frewer, K., Hargest, R. and Jiang, W. G. 2021. NUPR1 and its potential role in cancer and pathological conditions (Review). International Journal of Oncology 58(5), article number: 21. (10.3892/ijo.2021.5201)
- Sui, L., Ye, L., Sanders, A. J., Yang, Y., Hao, C., Hargest, R. and Jiang, W. G. 2021. Expression of death associated proteins DAP1 and DAP3 in human pancreatic cancer. Anticancer Research 41(5), pp. 2357-2362. (10.21873/anticanres.15010)
- Liu, C., Jiang, W., Zhang, L., Hargest, R. and Martin, T. A. 2021. SIPA1 Is a modulator of HGF/MET induced tumour metastasis via the regulation of tight junction-based cell to cell barrier function. Cancers 13(7), article number: 1747. (10.3390/cancers13071747)
- Hargest, R. 2021. Five thousand years of minimal access surgery: 1850 to 1990: Technological developments. Journal of the Royal Society of Medicine 114(1), pp. 19-29. (10.1177/0141076820967918)
- Gong, W., Martin, T. A., Sanders, A. J., Hargest, R., Jiang, A., Sun, P. and Jiang, W. G. 2020. Influence of anaesthetics on the production of cancer cell motogens, stromal cell-derived factor-1 and hepatocyte growth factor by fibroblasts. Oncology Letters 21(2), article number: 140. (10.3892/ol.2020.12401)
- Liu, C., Jiang, W., Hargest, R. and Martin, T. 2020. The role of SIPA1 in the development of cancer and metastases (Review). Molecular and Clinical Oncology 13(4), article number: 32. (10.3892/mco.2020.2102)
- Badder, L. M. et al. 2020. 3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitors. PLoS ONE 15(8), article number: e0235319. (10.1371/journal.pone.0235319)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
- Besneux, M. et al. 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68, pp. 247-256. (10.1007/s00262-018-2266-1)
- Soliman, F. and Hargest, R. 2018. Intestinal failure in gastrointestinal fistula patients. Surgery (Oxford) 36(5), pp. 245-251. (10.1016/j.mpsur.2018.03.001)
- Sahnan, K. et al. 2018. Developing a core outcome set for fistulising perianal Crohn's disease. Gut (10.1136/gutjnl-2017-315503)
- Hargest, R. 2018. Randomized controlled trial of standard closure of a stoma site vs biological mesh reinforcement: study protocol of the ROCSS trial. Colorectal Disease 20(2), pp. O46-O54. (10.1111/codi.13997)
- Osman, B., Roushias, S., Hargest, R. and Narahari, K. 2017. Migration of ventriculoperitoneal shunt to urethral and rectal orifices. BMJ Case Reports 2017, article number: 220187. (10.1136/bcr-2017-220187)
- Zabkiewicz, C., Resaul, J., Hargest, R., Jiang, W. G. and Ye, L. 2017. Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. Endocrine-Related Cancer 24(10), pp. R349-R366. (10.1530/ERC-17-0139)
- Zabkiewicz, C., Resaul, J., Hargest, R., Jiang, W. G. and Ye, L. 2017. Increased expression of follistatin in breast cancer reduces invasiveness and clinically correlates with better survival. Cancer Genomics and Proteomics 14(4), pp. 241-251. (10.21873/cgp.20035)
- Lee, M., Heywood, N., Sagar, P. M., Brown, S. R., Fearnhead, N. and Hargest, R. 2017. Association of Coloproctology of Great Britain and Ireland consensus exercise on surgical management of fistulating perianal Crohn's disease. Colorectal Disease 19(5), pp. 418-429. (10.1111/codi.13672)
- Gu, Y. et al. 2017. NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. Oncotarget 8(5), pp. 7753-7765. (10.18632/oncotarget.13949)
- Hargest, R. 2016. Feasibility study from a randomized controlled trial of standard closure of a stoma sitevsbiological mesh reinforcement. Colorectal Disease 18(9), pp. 889-896. (10.1111/codi.13310)
- Cornish, J. et al. 2016. Hughes Abdominal Repair Trial (HART) - Abdominal wall closure techniques to reduce the incidence of incisional hernias: study protocol for a randomised controlled trial. Trials 17(1), pp. 454. (10.1186/s13063-016-1573-0)
- Teagle, A. R., Birchall, J. C. and Hargest, R. 2016. Gene therapy for pyoderma gangrenosum: optimal transfection conditions and effect of drugs on gene delivery in the HaCaT cell line using cationic liposomes. Skin Pharmacology and Physiology 29, pp. 119-129. (10.1159/000444859)
- Satherley, L., Sun, P. H., Ke, J., Mason, M. D., Hargest, R., Jiang, W. G. and Ye, L. 2016. Prostate Apoptosis Response-4 (PAR4) suppresses growth and invasion of breast cancer cells and is positively associated with patient survival. Anticancer Research 36(3), pp. 1227-1236.
- Greensmith, M., Cho, J. and Hargest, R. 2016. Changes in surgical training opportunities in Britain and South Africa. International Journal of Surgery 25, pp. 76-81. (10.1016/j.ijsu.2015.11.052)
- Collins, R. J., Jiang, W. G., Hargest, R., Mason, M. D. and Sanders, A. J. 2015. EPLIN: a fundamental actin regulator in cancer metastasis?. Cancer and Metastasis Reviews 34(4), pp. 753-764. (10.1007/s10555-015-9595-8)
- Soliman, F., Sturgeon, G. and Hargest, R. 2015. Revisiting an ancient treatment for transphincteric fistula-in-ano 'There is nothing new under the sun' Ecclesiastes 1v9. Journal of the Royal Society of Medicine 108(12), pp. 482-489. (10.1177/0141076815588322)
- Li, J., Ye, L., Sun, P., Satherley, L., Hargest, R., Zhang, Z. and Jiang, W. G. 2015. MTA1 is up-regulated in colorectal cancer and is inversely correlated with lymphatic metastasis. Cancer Genomics and Proteomics 12(6), pp. 339-346.
- Satherley, L., Ye, L., Hargest, R. and Jiang, W. G. 2015. Downstream of tyrosine kinase 7 (DOK7) variant expression and function in human colorectal cancer [Abstract]. European Journal of Cancer 51(S3), pp. S27. (10.1016/S0959-8049(15)30004-6)
- Ji, J., Jia, S., Jia, Y., Ji, K., Hargest, R. and Jiang, W. G. 2015. WISP-2 in human gastric cancer and its potential metastatic suppressor role in gastric cancer cells mediated by JNK and PLC-γ pathways. British Journal of Cancer 113(6), pp. 921-933. (10.1038/bjc.2015.285)
- Ji, K., Cui, Y., Hargest, R. and Jiang, W. G. 2015. VILIP-1 plays a suppressive role in the motility of colorectal cancer cells and the inhibition involves the regulation of mmps via jnk signalling pathway. Anticancer Research 35(7), pp. 4332-4333.
- Satherley, L., Jiang, W. G., Hargest, R., Torkington, J. and Davies, M. 2015. Expression of lymphangiogenic factors Vegf-C and Vegf-D and impact of Vegf-D knockout on tubule formation in human colorectal cancer [Abstract]. British Journal of Surgery 102(s1), pp. 8-8., article number: 700. (10.1002/bjs.9735)
- Teagle, A. and Hargest, R. 2014. Management of pyoderma gangrenosum. Journal of the Royal Society of Medicine 107(6), pp. 228-236. (10.1177/0141076814534407)
- Satherley, L., Ye, L., Hargest, R. and Jiang, W. G. 2014. DOK7 expression in colorectal cancer cells and association with clinical and prognostic outcome [Abstract]. British Journal of Surgery 101(S4), pp. 12., article number: O34. (10.1002/bjs.9508)
- Jia, Y., Ye, L., Ji, K., Zhang, L., Hargest, R., Ji, J. and Jiang, W. G. 2014. Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. British Journal of Cancer 110(2), pp. 421-429. (10.1038/bjc.2013.712)
- Power, K., Davies, M. M., Hargest, R., Phillips, S., Torkington, J. and Morris, C. 2014. A case-control study of risk factors for wound infection in a colorectal unit. Annals of the Royal College of Surgeons of England 96(1), pp. 37-40. (10.1308/003588414X13824511650137)
- Jia, Y. et al. 2014. Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death. Oncology Reports 31(1), pp. 175-182. (10.3892/or.2013.2866)
- Ji, K., Ye, L., Ruge, F., Hargest, R., Mason, M. D. and Jiang, W. G. 2014. Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer. BMC Cancer 14, article number: 723. (10.1186/1471-2407-14-723)
- Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
- Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
- Frewer, N. et al. 2013. Potential implication of IL-24 in lymphangiogenesis of human breast cancer. International Journal of Molecular Medicine 31(5), pp. 1097-1104. (10.3892/ijmm.2013.1319)
- Chong, R. et al. 2013. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. Journal of Controlled Release 166(3), pp. 211-219. (10.1016/j.jconrel.2012.12.030)
- Frewer, K., Sanders, A. J., Owen, S., Frewer, N., Hargest, R. and Jiang, W. G. 2013. A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics and Proteomics 10(4), pp. 187-196.
- Chong, R. H. et al. 2013. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. Journal of Controlled Release 166(3), pp. 211. (10.1016/j.jconrel.2012.12.030)
- Blake, P., Delicata, R., Cross, N., Sturgeon, G. and Hargest, R. 2012. Large bowel obstruction due to colorectal carcinoma can be safely treated by colonic stent insertion - case series from a UK district general hospital. Colorectal Disease 14(12), pp. 1489-1492. (10.1111/j.1463-1318.2012.03035.x)
- Ji, K. et al. 2012. Expression of signal-induced proliferation-associated gene 1 (SIPA1), a rapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. Cancer Genomics and Proteomics 9(5), pp. 321-327.
- Chong, R., Coulman, S., Saller, V., Pearton, M., Shah, A., Hargest, R. and Birchall, J. C. 2011. Nucleic acid delivery to skin for the potential treatment of dermatopathogenic conditions [Abstract]. Human Gene Therapy 22(10), pp. A82-A82.
- Teagle, A., Birchall, J. C. and Hargest, R. 2011. The effect of drugs commonly used for pyoderma gangrenosum on the efficiency of gene transfer to human keratinocytes. Human Gene Therapy 22(10), pp. A94-A94.
- Teagle, A., Birchall, J. C. and Hargest, R. 2011. The effect of drugs commonly used for pyoderma gangrenosum on the efficiency of gene transfer to human keratinocytes [Abstract]. British Journal of Surgery 98, pp. 40-40. (10.1002/bjs.7577/abstract)
- Hardwicke, J., Wright, T. C., Hargest, R. and Dickson, W. 2010. The use of the Flexi-Seal®Faecal Management System in laparostomy wounds involving enterocutaneous fistula. Annals of the Royal College of Surgeons of England 92(4), pp. e12-e14. (10.1308/147870810X12659688851834)
- Zimbwa, T. A., Owen, R., Thomas, G., Hargest, R. and Williams, G. T. 2010. An unusual complication of colitis. Gut 59(3), pp. 364-364. (10.1136/gut.2009.179689)
- Stephens, M. and Hargest, R. 2009. The post-CCT subconsultant grade: the case against / the case for. Bulletin of The Royal College of Surgeons of England 91(4), pp. 124-126. (10.1308/147363509X423788)
- Ganapathi, S., Evans, G. and Hargest, R. 2008. Bilateral breast metastases of a renal carcinoma: a case report and review of the literature. BMJ Case Reports 2008(Nov 12), article number: bcr0620080239. (10.1136/bcr.06.2008.0239)
Bywgraffiad
Anrhydeddau a dyfarniadau
Silver Scalpel Award 2017 - This prestigious award is given by the Associaiton of Surgeons in Training (ASIT) to the best surgical trainer in the UK. Following nomination by surgical trainees from Cardiff and further afield, ASIT visited Cardiff to interview myself and colleagues. Assessment was made across five domains - leadership, resourcefulness, training and development, professionalism and communication. Following the interivews, the final 3 candidates were assessed by a panel including the presidents of the four Royal Colleges of Surgery and chaired by Sir Bruce Keogh (NHS England Medical Director). The award was presented at the annual meeting of ASIT in Bournemouth in April 2017.
British Medical Journal Gastroenterology Team of the year award 2015
The Cardiff and Vale Health Board Intestinal Failure Team won the BMJ Gastroenterology team of the year award in 2014. This was for our work over the last 5 years to improve services for Welsh patients who require home total parenteral nutrition. Since I took on the surgical lead role in this team we have been able to offer surgery to patients in Wales, who would previously have had to travel to London or Manchester. The team provides very high standards of medical and nursing support, along with excellent surgical outcomes for those who require surgery.
NHS Award for improving patient care 2012
During my time as lead clinician for colorectal cancer (2010-15) the colorectal team at University Hospital of Wales won this award for introducing an Enhanced Recovery After Surgery (ERAS) program for patients undergoing surgery for colorectal cancer.
Aelodaethau proffesiynol
- General Medical Council
- Registered with GMC, with a licence to practice
- On the Specialist Register (General Surgery) since 1999
- Appeals Assessor
- Royal Society of Medicine (RSM)
- President Section of Surgery (2016-17)
- Trustee and member of RSM Council (2011-2019)
- Honorary Treasurer (2014-2019)
- Director of RSM International (2014–2019)
- Director of RSM Support Services (2014- 2019)
- Director of RSM Press (2012-2013)
- Treasurer of Surgical Section of RSM (2010-2012, 2021-present)
- Secretary of Surgical Section of RSM (2012-2013)
- Member of Coloproctology section of RSM
- Council member of Gastroenterology Section of RSM (2013-present)
- Royal College of Surgeons (RCS)
- Council member (2020-present)
- Academic representative on Welsh Board of RCS (2007-2015)
- RCS representative on Advisory Appointments Committees
- National Institute of Health and Care Excellence (NICE)
- Royal College of Surgeons representative on the management board of NICE- National Collaborating Centre for Cancer (2008-2016)
- British Association of Surgical Oncology
- Trustee and Member of BASO National Executive Committee (2011-2015)
- EJSO representative 2011-15
- Society of Academic and Research Surgeons
- Council member
- Member of Association of Coloproctology of Great Britain & Ireland (ACPGBI)
- Member of Disciplinary Panel of ACPGBI
- Member of British Society of Gastroenterology
- Member of Welsh Association of Gastroenterology and Endoscopy
- Member of International Society for Hereditary Gastrointestinal Tumours
- Member of Assoication of Surgeons of Great Britain and ireland
Safleoedd academaidd blaenorol
- 2000-2007 Honorary Lecturer, Cardiff University
Pwyllgorau ac adolygu
- Editorial and peer reviewing duties
- Recent Advances in Surgery
- Joint Editor (appointed 2015)
- Peer reviewer for the following journals:
- The Lancet
- Annals of Royal College of Surgeons
- British Journal of Surgery
- European Journal of Surgical Oncology
- Cellular Oncology
- Gut
- BMC Gastroenterology
- BMC Cancer
- International Journal of Dermatology Research and Therapy
- Journal of the Royal Society of Medicine
- World Journal of Surgery
- Peer reviewer for the following grant giving organisations:
- Royal College of Surgeons of England
- Department of Health in Scotland
Contact Details
+44 29206 87130
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell 3F08, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN